Realizing the potential of the revolution in cancer treatment depends on ensuring researchers, regulators, and clinicians have access to all the information they need to develop, approve, and prescribe new drugs – including patient adherence data. Nothing stops a drug … Read More
Author Archives: Bernard Vrijens
Smart Caps Improve Medication Adherence in Clinical Trials – It’s a Fact!
Poor medication adherence is a problem that has gone “unsolved” for decades. But combining smart caps with individualized feedback can drive the adherence that proves the investigational product efficacy and underwrites approvals. In this case study, we set out the … Read More
High Fidelity Measurement of Patients’ Medication Adherence: A Missing Link in Precision Medicine
The emergence of pharmacogenomics is an important milestone in the precision medicine journey – but the importance of measuring medicine adherence, an essential component in the complex pharmacokinetics/ pharmacodynamics equation, can often be overlooked. In this article, Bernard Vrijens, CEO … Read More
In a world of outcome-based pricing, can you afford to neglect patient adherence?
The emergence of outcome-based contracts in clinical research has placed an additional consideration on the already thorny issue of adherence. When drug companies are paid according to the real-world effectiveness of their products, ensuring people take the medications as prescribed … Read More
Adherence to Medication: The Missing Piece in the Pharmacogenomics Puzzle
If enacted, the US’ Right Drug Dose Now Act will place pharmacogenomics on the main stage of drug development and move us further into the personalized medicine era. By supporting the use of pharmacogenetic testing to prevent adverse events (AEs) … Read More
The Heart of the Matter: The Role of Medication Adherence Tools in Tackling the CVD Epidemic
Despite huge strides in how cardiovascular diseases (CVD) are treated in recent years, the conditions remain among the leading causes of morbidity and mortality worldwide. At least part of the problem is that even the most effective drugs will not … Read More
Exploring the Relationship Between Drug Forgiveness and Patient Adherence
With patient adherence thought to be lower than 50% 1, drug companies are increasingly maximizing dosages to bridge the gap at population scale – but are we overdosing individual patients as a result? The industry’s tendency to always aim for the … Read More
FDA Issues Draft Diversity Guidance to Improve Enrollment of Participants from Underrepresented Patient Populations
Diversity in clinical research is a growing concern for sponsors as many factors can influence how an individual may react to certain drugs: age, biological sex, disabilities, chronic comorbidities, geographical location, gender identity, race, and ethnic background. Thus, if the … Read More
Optimizing Study Design to Tackle Protocol Deviations in DCTs
Decentralized Clinical Trials (DCTs) are here to stay, as demonstrated by international regulators’ recent commitments to the model. But while the approach offers a multitude of benefits, from expanding access to increasing cohort diversity, it can also serve to magnify … Read More
Harnessing Digital Health Technology to Bolster Study Power
In a world of big tech, data is king. This slogan is far from news for the Biopharmaceutical Industry, but clinical trials are lengthy, complex, and expensive, meaning precious information isn’t always utilized to its maximum potential. In recent years, … Read More